Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023
November 06 2023 - 4:00PM
Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage biopharmaceutical
drug development company focused on advancing novel therapeutics
targeting degenerative retinal diseases that have significant unmet
medical needs, today announced that Belite Bio’s Chief
Scientific Officer, Nathan Mata will present at the Deutsche Bank
American Depositary Receipt (ADR) Virtual Investor Conference
(dbVIC) on November 8. This virtual investor conference is aimed
exclusively at introducing global companies with ADR programs to
investors.
DATE: |
November 8,
2023 |
TIME: |
11:00 AM ET |
LINK: |
https://bit.ly/3rhvMzf |
This will be a live, interactive online event in which investors
are invited to ask the company questions in real-time. If attendees
are not able to join the event live on the day of the conference,
an archived webcast will also be made available after the
event.
It is recommended that investors pre-register and run the online
system check to expedite participation and receive event
updates.
Participation is free of charge.
Recent Company Highlights
-
Tinlarebant is Belite Bio’s orally administered tablet intended to
slow disease progression in patients affected with Stargardt
Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry
Age-related Macular Degeneration (Dry AMD).
-
Currently, there are no FDA approved treatments for STGD1 and no
approved oral or non-invasive treatments for GA.
-
A fully enrolled, two-year global Phase 3 trial in adolescent STGD1
(the “DRAGON” study) subjects and a two-year global Phase 3 trial
in GA subjects (the “PHOENIX” study) are ongoing.
-
A two-year Phase 2 trial in adolescent STGD1 subjects shows that:
-
Tinlarebant was safe and well-tolerated with no withdrawals due to
adverse events.
-
Retinal imaging showed that 5 of 12 subjects remained free of
atrophic retinal lesions (referred to as definitely decreased
autofluorescence or DDAF) after 24 months of Tinlarebant
treatment.
-
A comparison of the 24-month DDAF lesion growth between
Tinlarebant-treated subjects and ProgStar participants possessing
similar baseline characteristics (aged ≤18 years) showed a
sustained lower DDAF lesion growth in Tinlarebant-treated subjects
over the 24-month treatment period (p<0.001).
-
42% of Tinlarebant-treated subjects (5 out of 12) did not develop
atrophic retinal lesions during the 24-month treatment period.
-
Visual acuity was stabilized in majority of subjects during the
study with a mean loss of five letters following 24 months of
treatment (a loss of <10 letters is not considered clinically
significant).
-
Tinlarebant has been granted Fast Track Designation and Rare
Pediatric Disease designation in the U.S., and Orphan Drug
Designation in the U.S. and Europe for the treatment of STGD1.
-
There are an estimated 20 million AMD patients in the U.S. and over
196 million patients worldwide with an estimated global direct
healthcare cost of US$255 billion.
About Belite Bio, Inc.
Belite Bio is a clinical-stage biopharmaceutical drug
development company focused on advancing novel therapeutics
targeting degenerative retinal diseases that have significant unmet
medical needs, such as STGD1 and GA in advanced Dry AMD, in
addition to specific metabolic diseases. For more information,
follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at
www.belitebio.com.
About Virtual Investor Conferences®Virtual
Investor Conferences (VIC) is the leading proprietary investor
conference series that provides an interactive forum for publicly
traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is
specifically designed to offer companies more efficient investor
access. Replicating the components of an on-site investor
conference, VIC offers companies enhanced capabilities to connect
with investors, schedule targeted one-on-one meetings and enhance
their presentations with dynamic video content. Accelerating the
next level of investor engagement, Virtual Investor Conferences
delivers leading investor communications to a global network of
retail and institutional investors.
ContactsBelite Bio,
Inc.Jennifer Wu ir@belitebio.com Argot
belitebio@argotpartners.com
Virtual Investor ConferencesJohn M. ViglottiSVP
Corporate Services, Investor AccessOTC Markets Group (212)
220-2221johnv@otcmarkets.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/f0f754ee-6fe3-43dd-b171-86f917dab9f7
Belite Bio (NASDAQ:BLTE)
Historical Stock Chart
From Apr 2024 to May 2024
Belite Bio (NASDAQ:BLTE)
Historical Stock Chart
From May 2023 to May 2024